This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Quest Diagnostics (DGX) Advances Access to Transplant Services
by Zacks Equity Research
Quest Diagnostics' (DGX) upgrade to advanced diagnostics and support services is likely to feature personalized patient access to service centers and mobile phlebotomists.
Is Avanos Medical (AVNS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Avanos Medical (AVNS) and Becton Dickinson (BDX) have performed compared to their sector so far this year.
QIAGEN's (QGEN) Expanded Test Menu Aids, FX Woe Lingers
by Zacks Equity Research
In terms of QIAstat-Dx, QIAGEN (QGEN) continues to witness increased demand for system placements and growing consumables usage around the world.
National Vision (EYE) Rides on Comps Growth Amid Macro Issues
by Zacks Equity Research
National Vision (EYE) continues to roll out its remote care capabilities, which provide doctors with additional levels of flexibility and expand exam capacity in many areas.
3 Reasons to Add Avanos (AVNS) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Illumina (ILMN) to Expand Genomics Capacity With New Pact
by Zacks Equity Research
Illumina's (ILMN) recent collaboration is built on the shared goal of the organizations to expand sequencing capabilities and capacity for all people in Africa.
Here's Why Investors Should Invest in Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on strong elective procedure recovery and commercial execution.
Illumina's (ILMN) NovaSeq X Exceeds 200 Order Milestone
by Zacks Equity Research
Illumina's (ILMN) NovaSeq X records the strongest pre-launch demand ever witnessed for any instrument.
3 Reasons to Retain Integer Holdings (ITGR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and a solid foothold in the broader MedTech space.
CVS Health's (CVS) New Initiatives Aid, Margin Woes Linger
by Zacks Equity Research
CVS Health (CVS) launches functionality that gives patients more choices and convenience in filling prescriptions.
Cardiovascular Systems (CSII) Finishes ECLIPSE Trial Enrollment
by Zacks Equity Research
Cardiovascular Systems' (CSII) ECLIPSE clinical trial data is likely to help physicians form an optimal treatment plan for patients with severely calcified coronary arteries.
Community Health (CYH) Divests Hospital for $92 Million
by Zacks Equity Research
Community Health (CYH) divests a healthcare facility in West Virginia, thereby reinforcing the sincere focus that it puts to shed non-core assets and use funds to grow well-performing business areas.
LabCorp (LH) Expands Colon Cancer Test Access With New Pact
by Zacks Equity Research
LabCorp's (LH) at-home collection kit will offer patients an additional and easier option to get screened for colon cancer.
Here's Why You Should Invest in Haemonetics (HAE) Right Now
by Zacks Equity Research
Investors are upbeat about Haemonetics (HAE) owing to impressive Plasma and Hospital business performance, with continued strength in the Hemostasis Management product line.
3 Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) broad array of services.
Masimo's (MASI) New FDA Clearance to Boost Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) receipt of the FDA's De Novo grant is expected to combat opioid overdoses by boosting patient monitoring.
3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio
by Zacks Equity Research
PacBio's (PACB) product development activities raise optimism about the stock.
Medtronic (MDT) Launches New Venture to Treat Kidney Failure
by Zacks Equity Research
Medtronic's (MDT) new venture is dedicated to reshaping kidney health and driving patient-centered technology solutions.
Tandem Diabetes (TNDM) Gains on Pump Sales, Margin Woe Stays
by Zacks Equity Research
Tandem Diabetes (TNDM) is now increasing its renewal numbers both in volume and rates.
Why You Should Add Hologic (HOLX) to Your Portfolio Now
by Zacks Equity Research
Hologic (HOLX) is currently well-positioned to achieve its full-year guidance of low double-digit organic growth ex-COVID in all three franchises, well above the 5-7% long-term growth rate.
Abbott's (ABT) Epic Max Tissue Valve Receives FDA Approval
by Zacks Equity Research
Abbott's (ABT) Epic Max design optimizes patient blood flow and has a low profile that makes future cardiac interventions simpler.
3 Reasons to Retain DaVita (DVA) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to the strength in its DaVita Kidney Care.
Neogen (NEOG) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Neogen (NEOG) delivers core growth in both the Food Safety and Animal Safety segments amid macroeconomic headwinds in the third quarter.
Catalent (CTLT) New Launch to Aid TPD Programs, Clinical Trials
by Zacks Equity Research
Catalent's (CTLT) latest launch will likely aid in advancing the rational selection of orally developable TPD candidates and their progress into clinical trials.
UnitedHealth (UNH) Arm to Reduce Prior Authorization Time
by Zacks Equity Research
UnitedHealth's (UNH) UnitedHealthcare business to lower the use of prior authorization process or preauthorization by almost 20%.